Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.10) earnings per share for the quarter, FiscalAI reports. Firefly Neuroscience had a negative return on equity of 94.68% and a negative net margin of 565.40%.The business had revenue of $0.51 million during the quarter.
Firefly Neuroscience Stock Performance
AIFF stock traded up $0.01 during midday trading on Tuesday, reaching $1.20. 9,895 shares of the company traded hands, compared to its average volume of 4,396,718. The firm has a market capitalization of $18.73 million, a price-to-earnings ratio of -1.90 and a beta of 0.57. Firefly Neuroscience has a 52-week low of $0.62 and a 52-week high of $3.63. The business has a 50 day moving average of $1.29 and a 200-day moving average of $1.46.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Firefly Neuroscience in the fourth quarter valued at $53,000. BlackRock Inc. purchased a new position in shares of Firefly Neuroscience during the 2nd quarter worth about $226,000. Geode Capital Management LLC grew its holdings in Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after purchasing an additional 58,067 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares during the last quarter. 4.96% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Get Our Latest Report on Firefly Neuroscience
About Firefly Neuroscience
Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.
The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.
Featured Stories
- Five stocks we like better than Firefly Neuroscience
- Rocket Lab’s Record Quarter Still Left Investors Waiting on Neutron
- AMD’s Helios Launch Could Create Winners Beyond AMD Stock
- Meta’s Muse Glimmer Release Reframes Its AI Spending Bet
- 3 Companies That Could Thrive While the Fed Holds Rates Steady
Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
